Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
CALC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Quote Panel
Key Metrics
prnewswire.com
7 hours ago
prnewswire.com
7 hours ago
prnewswire.com
7 hours ago
prnewswire.com
7 hours ago
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.82
vs -6.44
Q4.23
N/A
-0.23
vs -4.79
Q1.24
N/A
-0.43
vs -23.43
Q2.24
N/A
-0.52
vs -1.11
Q3.24
N/A
-0.50
vs -0.82
Q4.24
N/A
-0.34
vs -0.23
Q1.25
N/A
-0.36
vs -0.43
Q2.25
N/A
-0.40
vs -0.52
Q3.25
N/A
-0.41
vs -0.50
Q4.25
N/A
-0.38
vs -0.34
Sales Growth
YoY
Current
Estimates
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
60K vs NA
Q1.25
NA
NA vs NA
Q2.25
NA
NA vs NA
Q3.25
NA
NA vs NA
Q4.25
+55456%
33.3M vs 60K
Return on Equity
QoQ
Q1.23
-88%
-0.88
vs -0.21
Q2.23
-39%
-0.39
vs -0.88
Q3.23
-38%
-0.38
vs -0.39
Q4.23
-51%
-0.51
vs -0.38
Q1.24
+1%
0.01
vs -0.51
Q2.24
-29%
-0.29
vs 0.01
Q3.24
-62%
-0.62
vs -0.29
Q4.24
-30%
-0.30
vs -0.62
Q1.25
-46%
-0.46
vs -0.30
Q2.25
-98%
-0.98
vs -0.46
Institutionnal Ownership
QoQ
Q4.22
NA
NA
vs NA
NA
Q1.23
NA
NA
vs NA
NA
Q2.23
13
13
vs NA
NA
Q3.23
13
13
vs 13
NA
Q4.23
12
12
vs 13
-8%
Q1.24
20
20
vs 12
67%
Q2.24
21
21
vs 20
5%
Q3.24
24
24
vs 21
14%
Q4.24
29
29
vs 24
21%
Q1.25
30
30
vs 29
3%
Forecast
2026-Revenue
-295%2026-EPS
2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
No Data Available
Relative Strength
CALC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
NASDAQ
Unprofitable
Unprofitable
0.03Â ( 1.13%)
Relative Strenght
84
Volume Buzz
-32%
Earning Acce
No
Dist 52w H.
51%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How CALC compares to sector?
CALC
-2114x